Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.

about

Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.

Item

http://www.wikidata.org/entity/Q47261717

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy of EGFR tyrosine kina ...... ons: A retrospective analysis.

@en

Efficacy of EGFR tyrosine kina ...... ons: A retrospective analysis.

@nl

type

Item

label

Efficacy of EGFR tyrosine kina ...... ons: A retrospective analysis.

@en

Efficacy of EGFR tyrosine kina ...... ons: A retrospective analysis.

@nl

prefLabel

Efficacy of EGFR tyrosine kina ...... ons: A retrospective analysis.

@en

Efficacy of EGFR tyrosine kina ...... ons: A retrospective analysis.

@nl

P1476

Efficacy of EGFR tyrosine kina ...... ons: A retrospective analysis.

@en

P2093

Guang Han

http://www.w3.org/2001/XMLSchema#string

Gui-Fang Yang

http://www.w3.org/2001/XMLSchema#string

Hua-Li Liu

http://www.w3.org/2001/XMLSchema#string

Jin-Ming Yu

http://www.w3.org/2001/XMLSchema#string

Jing-Ping Yuan

http://www.w3.org/2001/XMLSchema#string

Min Peng

http://www.w3.org/2001/XMLSchema#string

Qi-Bin Song

http://www.w3.org/2001/XMLSchema#string

Yi-Ming Weng

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

EGFR testing in lung cancer is ready for prime time

Cancer statistics, 2016

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

P2888

s11596-017-1819-4

P304

864-872

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11596-017-1819-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29270745

http://www.w3.org/2001/XMLSchema#string